Vertex Pharmaceuticals
Pharmaceuticals
VRTX
$ 247 2.4
Share price
$ 63 bn
Market Cap
$ 63 bn
Enterprise Value
Carbon footprint
Primary Climate Goal
Vertex Pharmaceuticals aims to reduce Scope 1 + 2 by 20% by 2023 from a base year 2018
This target is most likely outdated and the company appears to have already achieved it
This target has not been verified as science based according to SBTi
GHG emissions and Carbon intensity
Vertex Pharmaceuticals reported Total CO2e Emissions - Market-Based Scope 1 + Scope 2 for the twelve months ending 31 December 2020 at 13 Kt (-0.38 /-2.7% y-o-y). Also positively, carbon intensity was down at 2.2 t (-1.1 /-33.3% y-o-y).
No public disclosure of Scope 3 emissions has been found for Vertex Pharmaceuticals at the moment.
The company is committed to reducing Scope 1 + 2 by 20% by 2023 from a base year 2018, which it appears to have already achieved as of 2020. This target, however, has not been recognised as science-based (and as aligned with Paris Agreement) by the SBTi.
Copyright © 2022 Exerica. All rights reserved.